Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2023 Earnings Call Transcript February 29, 2024 Xenon Pharmaceuticals Inc. beats earnings...
2 months ago

VANCOUVER, British Columbia, May 07, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused...
2 weeks ago

Summary · Today, we focused on Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on developing therapeutics for...
3 months ago

Phase 3 epilepsy program continues to progress with anticipated completion of patient enrollment in X-TOLE2 in late 2024 to early 2025.
2 weeks ago

Xenon Pharmaceuticals has reported topline data from the X-NOVA clinical trial of XEN1101 to treat patients with moderate to severe MDD.
5 months ago

Xenon (NASDAQ:XENE) Pharmaceuticals Incorporated (ticker: XENE), a clinical-stage biopharmaceutical company, provided updates on its...
2 weeks ago

Despite a recent Phase II miss, Xenon Pharmaceuticals is forging ahead with its candidate for major depressive disorder, offering 8.4...
5 months ago

Xenon Pharmaceuticals (XENE) has released an update. Xenon Pharmaceuticals Inc., a company dedicated to developing treatments for neurological and...
1 month ago

Xenon Pharmaceuticals' phase 2 major depressive treatment did not show a statistically significant reduction in depression symptoms,...
5 months ago

The funding will advance Biolexis' development pipeline, which includes a range of metabolic drug candidates. These drugs have the potential to...
5 months ago